Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Maximum estimated study duration per patient: either 27 weeks (patients randomized to insulin glargine arm) or 51 weeks (patients randomized to liraglutide arm) broken down as follow: * A 2-week of screening period, * A 24-week comparative period, * A 24-week extension period (only for patients treated with liraglutide, not adequately controlled at the end of the comparative period), * A 1-week follow-up period